Single-Dose Psilocybin Treatment for Major Depressive Disorder
2023 · JAMA · 438 citations
https://doi.org/10.1001/jama.2023.14530
S
Sandeep M. Nayak
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
94
Papers
1.8K
Citations
22
h-index
39
i10-index
Sandeep M. Nayak is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Psychedelics and Drug Studies & Chemical synthesis and alkaloids & Neurotransmitter Receptor Influence on Behavior. The author has an h-index of 22, co-authored 80 publications.
ORCID: 0000-0002-6832-0639Papers by this author
worksNaturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
2023 · Frontiers in Psychiatry · 73 citations
https://doi.org/10.3389/fpsyt.2023.1199642
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder
2024 · PLoS ONE · 55 citations
https://doi.org/10.1371/journal.pone.0300501
The Hopkins-Oxford Psychedelics Ethics (HOPE) Working Group Consensus Statement
2024 · The American Journal of Bioethics · 25 citations
https://doi.org/10.1080/15265161.2024.2342764
IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models
2023 · Pharmacological Research · 11 citations
https://doi.org/10.1016/j.phrs.2023.106998
Psychedelic medicine: mechanisms, evidence, and translation to practice
2026 · BMJ · 0 citations
https://doi.org/10.1136/bmj-2024-081723
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat